Skip to main content
Fig. 1 | Trials

Fig. 1

From: Investigating the use of finerenone in children with chronic kidney disease and proteinuria: design of the FIONA and open-label extension studies

Fig. 1

Study design. Dagger indicates RAASi = ACEi or ARB. Double dagger indicates mandatory for at least 30 days before screening. ACEi angiotensin-converting enzyme inhibitor, ARB angiotensin receptor blocker, EOT end of treatment, FIN finerenone, OLE open-label extension, RAASi renin–angiotensin–aldosterone system inhibitor

Back to article page

Trials

ISSN: 1745-6215